#### CANTOR COLBURN LLP

INTELLECTUAL PROPERTY ATTORNEYS
55 Griffin Road South
Bloomfield, CT 06002

RECEIVED CENTRAL FAX CENTER SEP 3 0 2004

Tel: (860) 286-2929 Fax: (860) 286-0115

## FACSIMILE TRANSMITTAL SHEET

DATE:

September 30, 2004

TO:

USPTO IDS Division

cc:

FAX NO.: (703) 872-9306

(105) 012-2500

FROM: Karen A. LeCuyer

TOTAL NUMBER OF PAGES SENT (INCLUDING THIS COVER SHEET): (14) - including this cover sheet

COMMENTS:

RE:CSO-0001-P

If there are any problems with this facsimile transmission, please contact Leila Leahy at: (860) 286-2929, Ext. 1187. Thank you.

IMPORTANT: This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that reading, disseminating, distributing or copying this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone, and return the original message to us at the above address via the U.S. Postal Service. Thank you.

In Re Application Of: CHEN  Application No. Filing Date Examiner Customer No. Group Art Unit 10/647,458 August 1, 2003 NYA 23413 1614 2036  Title: BOTANICAL EXTRACT COMPOSITIONS AND METHODS OF USE  Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450  37 CFR 1.97(b)  1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.  37 CFR 1.97(c)  2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(c). The Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:  the statement specified in 37 CFR 1.97(e).  OR  the fee set forth in 37 CFR 1.17(p).	TRANSMITTA	L OF INFORMA (Under 37 CFR	TION DISCLOSURE STA R 1.97(b) or 1.97(c))	TEMENT	11	ket No. -0001-P
Application No. Filing Date  10/647,458  August 1, 2003  NYA  23413  1614  2036  Title: BOTANICAL EXTRACT COMPOSITIONS AND METHODS OF USE  Address to:  Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450  37 CFR 1.97(b)  1.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application, before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.  37 CFR 1.97(c)  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:    the statement specified in 37 CFR 1.97(e):	In Re Application Of	: CHEN				
Title: BOTANICAL EXTRACT COMPOSITIONS AND METHODS OF USE  Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450  37 CFR 1.97(b)  1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.  37 CFR 1.97(c)  2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:  □ the statement specified in 37 CFR 1.97(e):  OR	Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
Address to:  Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450  37 CFR 1.97(b)  1. Image: The information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.  37 CFR 1.97(c)  2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:    the statement specified in 37 CFR 1.97(e):  OR	10/647,458	August 1, 2003	NYA	23413	1614	2036
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450  37 CFR 1.97(b)  1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.  37 CFR 1.97(c)  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:  the statement specified in 37 CFR 1.97(e):  OR	Title: BOTANICA	L EXTRACT COMP	POSITIONS AND METHODS (	OF USE		
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450  37 CFR 1.97(b)  1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.  37 CFR 1.97(c)  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:  the statement specified in 37 CFR 1.97(e):  OR						
Commissioner for Patents P.O. Box 1450 Alexandrta, VA 22313-1450  37 CFR 1.97(b)  1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.  37 CFR 1.97(c)  2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:  the statement specified in 37 CFR 1.97(e):  OR	•					
<ul> <li>The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</li> <li>37 CFR 1.97(c)</li> <li>The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</li> <li>the statement specified in 37 CFR 1.97(e):</li> </ul>			Commissioner for Pater P.O. Box 1450			· · · · · · · · · · · · · · · · · · ·
of a national application other than a continued prosection application three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filling of a request for continued examination under 37 CFR 1.114.  37 CFR 1.97(c)  2.  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:  The statement specified in 37 CFR 1.97(e):  OR						
<ul> <li>The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</li> <li>the statement specified in 37 CFR 1.97(e):</li> </ul>	of a nation three mon	nal application other oths of the date of er	than a continued prosecution ntry of the national stage as se of a first Office Action on the n est for continued examination u	application and it forth in 37 CF nerits, or before	R 1.491 in an in the mailing of a	nternational
· OR	CFR 1.97	(b), provided that the	tatement submitted herewith is the Information Disclosure State 1 1 1 1 2	ment is filed bunder 37 CFI	R 1.311, or an	B
	☐ the	statement specified	in 37 CFR 1.97(e);			
□ the fee set forth in 37 CFR 1.17(p)		•	OR			,
	☐ the	fee set forth in 37 C	FR 1.17(p).			•
			·			

TRANSMITTA	L OF INFORMA (Under 37 CFF	TION DISCLOS R 1,97(b) or 1.97(		TEMENT		cket No. 9-0001-P
In Re Application	n: CHEN					
Application No.	Filing Date	Examine	er	Customer No.	Group Art Unit	Confirmation No.
10/647,458	August 1, 2003	NYA		23413	1614	2036
Title: BOTANIC	AL EXTRACT COM	POSITIONS AND I	METHODS (	of use		
as describe  Ch Ch Ch Payment b WARNING included c Certific  I certify that this account is bein Patent and Trace 9/30/04  Letta Leahy Typed or	the amount of or is hereby authorized below. arge the amount of edit any overpaymen arge any additional five credit card. Form Provided the control of this form. Provided the control of the company of the control of	is attacted to charge and created to charge and created to charge and created.  TO-2038 is attached is form may become credit card informay Facsimile*  To the United States (703) 872-9306	ched. edit Deposit  od. ne public. Comation and  Comation and  Commission and 22313-14	Account No.  Credit card info authorization ortificate of Mai certify that this counited States Post class mail in stoner for Patents.  (Date)  Signature of Patents.	ormation should on PTO-2038.  ling by First Claimespondence is better with suff an envelope at P.O. Box 1450, Alterson Mailing Correspondence of Person Mailing Corre	ss Mail  ing deposited icient postage addressed to exandra, VA
CANTOR COLBU Customer No.: 234 Registration No.: 5	13		,			^
				: :		
co:						

Lelieger

NO.562

CSO-0001-P

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Sophie Chen	Group Art Unit: 1614
Serial No.:	10/647,458	Examiner:
Filing Date:	August 1, 2003	NYA
For:	BOTANICAL EXTRACT () COMPOSITIONS AND METHODS	RECEIVED CENTRAL FAX CENTER
	OF USE	SEP 3 0 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose, submitted herewith is form PTO-A820 (PTO-1449) listing publication(s) of which those designated by 37 CFR § 1.56 are aware. Copies of the non-United States patents or published applications are enclosed.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made, or an admission that the information cited is, or is considered to be, material to patentability.

Respectfully submitted,

CANTOR COLBURN LLP

Karen A. LeCuyer Ph.D Registration No. 51,928

Date: September 30, 2004 Customer No. 23,413

(860) 286-2929

# JUL 06 2004

From the INTERNATIONAL SEARCHING AUTHORITY

To:

CANTOR COLBURN LLP Attn. Reimer, Leah M. 55 Griffin Road South Bloomfield, CT 06002 UNITED STATES OF AMERICA	OR THE DECLARATION  (PCT Rule 44.1)
	Date of mailing (day/month/year) 01/07/2004
Applicant's or agent's file reference	FOR FURTHER ACTION See paragraphs 1 and 4 below
CSO-0001PF-PCT	International filing date
International application No. PCT/US 03/24088	(day/month/year) 01/08/2003
Applicant	
CHEN, Sophie	
The applicant is hereby notified that the International Search Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the claim.	ns of the International Application (see Rule 46):
When? The time limit for filing such amendments is normal international Search Report; however, for more detailed.	ally 2 months from the date of transmittal of the etails, see the notes on the accompanying sheet.
Where? Directly to the International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Pascimile No.: (41-22) 740.14.85	
For more detailed instructions, see the notes on the accu	
2, The applicant is hereby notified that no International Searce Article 17(2)(a) to that effect is transmitted herewith.	h Report will be established and that the declaration under
3. With regard to the protest against payment of (an) additi	onal fee(s) under Rule 40.2, the applicant is notified that:
applicant's request to reliward the texts of sour are pro-	en transmitted to the International Bureau together with the trest and the decision thereon to the designated Offices.
	plicant will be notified as soon as a decision is made.
4. Further action(s): The applicant is reminded of the following:	
Shortly after 18 months from the priority date, the international if the applicant wishes to avoid or postpone publication, a notic priority claim, must reach the international Bureau as provided completion of the technical preparations for international public	in Rules 90 <i>bls.</i> 1 and 90 <i>bls.</i> 3, respectively, before the extlon.
Within 19 months from the priority date, a demand for Internation wishes to postpone the entry into the national phase until 30 m	nal preliminary examination must be filed if the applicant lonths from the priority date (in some Offices even later).
Wishes to positione the entry into the applicant must perform the priority date, the applicant must perfore all designated Offices which have not been elected in the priority date or could not be elected because they are not bour	orm the prescribed acts for entry into the national phase

Name and mailing address of the International Searching Authority European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijewijk Tei, (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016

Authorized officer

Sandrine Polenzani

Form PCT/ISA/220 (July 1998)

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative instructions, respectively.

#### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the International preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

#### What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the international Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

#### When?

Within 2 months from the date of transmittal of the international search report or 18 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the international Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Auje 46.1).

#### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international prollminary examination has been/is filed, see below.

#### How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

#### What documents must/may accompany the amendments?

#### Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the International application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

P. 7

- the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed:
- (v) the claim is the result of the division of a claim as filed.

# The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51];
   \*Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers: claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
   "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
   "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

#### "Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1),"

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

# Consequence if a demand for international preliminary examination has already been filed

If, at the time of filling any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filling the amendments (and any statement) with the International Bureau, also fill with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.9(a) and 62.2, first sentence). For further information, see the Notes to the demand form (POT/IPEA/401).

# Consequence with regard to translation of the International application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

# INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference  CBO - 0001PF - PCT	FOR FURTHER see Notification to (Form POT/ISA/S	of Fransmittal of International Search Report 220) as well as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/US 03/24088	01/08/2003	06/03/2002
Applicant		
	1	
CHEN, Sophie		
This international Search Report has be according to Article 18. A copy is being	en prepared by this international Searching Aut transmitted to the international Bureau.	honty and is transmitted to the applicant
This International Search Report consist It is also accompanied	ats of a total of <u>07</u> sheets. by a copy of each prior art document cited in this	s report.
1. Basis of the report	:	:
<ul> <li>With regard to the language, the language in which it was filed, to</li> </ul>	ne international search was carried out on the ba unless otherwise indicated under this item.	
	n was carried out on the basis of a translation of ).	
was sarded out on the DRSIS DI	life sedaeline damis .	international application, the international search
contained in the intern	ational application in written form. nternational application in computer readable to	m.
filed together with the	y to this Authority in written form.	•
- Land - January anth	on this Authority in computer readble form.	
the statement that the	subsequently furnished written sequence listing	
the statement that the furnished	Information recorded in computer readable form	is identical to the written sequence listing has been
Cortain eleima wara	found unsearchable (See Box I).	•
The state of Succession in		
a. X Unity of invention is	Warning Co.	
4. With regard to the title,		
the text is approved a	submitted by the applicant.	
] =	whiched by this Authority to read as follows:	
BOTANICAL EXTRACT CO	OMPOSITIONS WITH ANTI-CANCER	OR PHYTOESTROGENIC ACTIVITY
5. With regard to the abstract,		
the text is approved a the text has been est within one month from	U the date of maintager the stress required	ority as it appears in Box III. The applicant may, report, submit comments to this Authority.
6. The figure of the drawings to be	published with the abstract is Figure No.	1
x as suggested by the	applicant.	None of the figures.
because the applicar	t failed to suggest a figure.	
I E	etter characterizes the invention.	

Form PCT/ISA/210 (first sheet) (July 1998)

вох з — Opservations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Although claims 1-6 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X Claims Nos.:
3. Claims Nos.; because they are dependent claims and are not draited in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.;
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1 (part), 2, 3-7 (part), 8, 9-Il (part)
Remark on Protest  The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

page 1 of 2

# FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 1-6 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: -

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box 1.2

Claims Nos.: -

The formula given in claim 1 is not clear. Therefore the search has been carried out for a prenyl flavonoid represented by the formula in claim 1 with the proviso that at least one of R31 and R30 (instead of R33) is 3-methyl-2-butenyl. R33 can't be isoprenyl since an alkenyl substituent is not allowed for R33 (see the formulae in claims 1 and 7).

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

International Application No. PCT/ US 03/24088

# FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1 (part.), 2, 3-7 (part.), 8, 9-11 (part.)

Compositions comprising an anti-cancer agent and a prenyl flavonoid and their use for the treatment of cancer

2. claims: 1 (part.), 3-7 (part.), 9-11 (part.)

Compositions comprising an anti-cancer agent and formonometin and their use for the treatment of cancer

According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61K A61P IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, SCISEARCH, PASCAL, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication. where appropriate, of the relevant passages Relevant to claim No. EP 1 159 963 A (PROTEIN TECH INT) 5 December 2001 (2001-12-05) page 9, lines 37-46; claims 1.7 X 1-11 Y JANG, DAE SIK ET AL: "Prenylated 1-11 Υ flavonoids of the leaves of Macaranga conifera with inhibitory activity against cyclooxygenase-2" PHYTOCHEMISTRY (ELSEVIER) (2002), 61(7), 867-872, XP002269642 \* compounds 3,4,5 \* abstract Patent family members are listed in annex, Further documents are listed in the continuation of box C. Special categories of cited documents : "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document delining the general state of the art which is not considered to be of particular relevance invention "E" sariier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to Involve an inventive step when the document is taken alone filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication data of another citation or other special reason (es specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the International search Date of mailing of the Infernational search report D 1 07. 2004 10 February 2004 Authorized officer Name and mailing address of the ISA Europsan Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 MV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Friederich, M

Form PCT/ISA/210 (second sheet) (January 2004)

NO.562

PATENT ABSTRACTS OF JAPAN vol. 1998, no. 03, 27 February 1998 (1998-02-27) % JP 09 301915 A (SANKYO CO LTD), 25 November 1997 (1997-11-25) abstract		FUKAI, TOSHIO ET AL: "Cytotoxic activity of low molecular weight polyphenols against human oral tumor cell lines" ANTICANCER RESEARCH (2000), 20(4), 2525-2536, XP001016407 table 1	1-11
	,	vol. 1998, no. 03, 27 February 1998 (1998-02-27) & JP 09 301915 A (SANKYO CO LTD), 25 November 1997 (1997-11-25)	1-11
		man of the man in the	
	,		
	ĺ		
			<i>y</i>
	!		-
	,		
· · · · · · · · · · · · · · · · · · ·			·

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

					meneor(e)		uaw	
EP 11	59963	A	05-12-2001	EP	1159963 A1		05-12-2001	
JP 09	301915	Α	25-11-1997	NONE				
				,				
		•	1		,			
					•			
			•		`			
		•	•			•	•	
	•		••**	•••	. •			
					•			
			•					
•					-			
•				•	•	,		
		,						
				•			·	
			,					
• •								
			•			-		